The global immune thrombocytopenic purpura therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of immune thrombocytopenic purpura and the introduction of new drugs in the market.
The global immune thrombocytopenic purpura therapeutics market is segmented on the basis of type, application, and region. On the basis of type, it is classified into eltrombopag olamine, fostamatinib disodium, G2045, avatrombopag and B655064.On the basis of application it is classified into hospital and clinic. On the basis of region it includes North America (US, Canada), Latin America (Mexico), Europe (Germany), Asia Pacific (China) and Middle East & Africa (Saudi Arabia).
-The global Immune Thrombocytopenic Purpura Therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period, 2018-2025.
-The global Immune Thrombocytopenic Purpura Therapeutics market is expected to reach USD 1,890 million by 2025 from USD 1,200 million in 2018.
-Immune Thrombocytopenic Purpura Therapeutics are used for the treatment of immune thrombocytopenia purpura (ITP). The major factors driving the growth of this market are increasing prevalence of ITP and rising awareness about its treatment options.
Industry Growth Insights published a new data on “Immune Thrombocytopenic Purpura Therapeutics Market”. The research report is titled “Immune Thrombocytopenic Purpura Therapeutics Market research by Types (Eltrombopag Olamine, Fostamatinib Disodium, GL-2045, Avatrombopag, BI-655064, Others), By Applications (Hospital, Clinic, Others), By Players/Companies Amgen Inc., Baxalta Incorporated, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai, Hansa Medical AB, Immunomedics, Inc., Intas Pharmaceuticals Ltd., Jiangsu Hengrui Medicine Co., Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Novartis AG, Pfizer Inc.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Immune Thrombocytopenic Purpura Therapeutics Market Research Report
By Type
Eltrombopag Olamine, Fostamatinib Disodium, GL-2045, Avatrombopag, BI-655064, Others
By Application
Hospital, Clinic, Others
By Companies
Amgen Inc., Baxalta Incorporated, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai, Hansa Medical AB, Immunomedics, Inc., Intas Pharmaceuticals Ltd., Jiangsu Hengrui Medicine Co., Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Novartis AG, Pfizer Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Immune Thrombocytopenic Purpura Therapeutics Market Report Segments:
The global Immune Thrombocytopenic Purpura Therapeutics market is segmented on the basis of:
Types
Eltrombopag Olamine, Fostamatinib Disodium, GL-2045, Avatrombopag, BI-655064, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen Inc.
- Baxalta Incorporated
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eisai
- Hansa Medical AB
- Immunomedics, Inc.
- Intas Pharmaceuticals Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.
- Merck & Co., Inc.
- Momenta Pharmaceuticals, Inc.
- Novartis AG
- Pfizer Inc.
Highlights of The Immune Thrombocytopenic Purpura Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Eltrombopag Olamine
- Fostamatinib Disodium
- GL-2045
- Avatrombopag
- BI-655064
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immune Thrombocytopenic Purpura Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Immune Thrombocytopenic Purpura Therapeutics is a biotechnology company focused on the development and commercialization of novel therapeutics for immune thrombocytopenic purpura (ITP). ITP is a rare blood disorder characterized by low platelet counts that can lead to serious complications, including death. ITP therapies are currently available only through prescription from a healthcare provider. Immune Thrombocytopenic Purpura Therapeutics' goal is to develop and commercialize novel therapeutics that address the underlying causes of ITP, thereby providing patients with more options for treatment.
Some of the key players operating in the immune thrombocytopenic purpura therapeutics market are Amgen Inc., Baxalta Incorporated, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai, Hansa Medical AB, Immunomedics, Inc., Intas Pharmaceuticals Ltd., Jiangsu Hengrui Medicine Co., Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Novartis AG, Pfizer Inc..
The immune thrombocytopenic purpura therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Immune Thrombocytopenic Purpura Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Immune Thrombocytopenic Purpura Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Immune Thrombocytopenic Purpura Therapeutics Market - Supply Chain
4.5. Global Immune Thrombocytopenic Purpura Therapeutics Market Forecast
4.5.1. Immune Thrombocytopenic Purpura Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Immune Thrombocytopenic Purpura Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Immune Thrombocytopenic Purpura Therapeutics Market Absolute $ Opportunity
5. Global Immune Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Type
5.3.1. Eltrombopag Olamine
5.3.2. Fostamatinib Disodium
5.3.3. GL-2045
5.3.4. Avatrombopag
5.3.5. BI-655064
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Immune Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Immune Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Immune Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Immune Thrombocytopenic Purpura Therapeutics Demand Share Forecast, 2019-2026
9. North America Immune Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Type
9.7.1. Eltrombopag Olamine
9.7.2. Fostamatinib Disodium
9.7.3. GL-2045
9.7.4. Avatrombopag
9.7.5. BI-655064
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Immune Thrombocytopenic Purpura Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Type
10.7.1. Eltrombopag Olamine
10.7.2. Fostamatinib Disodium
10.7.3. GL-2045
10.7.4. Avatrombopag
10.7.5. BI-655064
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Immune Thrombocytopenic Purpura Therapeutics Demand Share Forecast, 2019-2026
11. Europe Immune Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Type
11.7.1. Eltrombopag Olamine
11.7.2. Fostamatinib Disodium
11.7.3. GL-2045
11.7.4. Avatrombopag
11.7.5. BI-655064
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Immune Thrombocytopenic Purpura Therapeutics Demand Share, 2019-2026
12. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Type
12.7.1. Eltrombopag Olamine
12.7.2. Fostamatinib Disodium
12.7.3. GL-2045
12.7.4. Avatrombopag
12.7.5. BI-655064
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Type
13.7.1. Eltrombopag Olamine
13.7.2. Fostamatinib Disodium
13.7.3. GL-2045
13.7.4. Avatrombopag
13.7.5. BI-655064
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Immune Thrombocytopenic Purpura Therapeutics Market: Market Share Analysis
14.2. Immune Thrombocytopenic Purpura Therapeutics Distributors and Customers
14.3. Immune Thrombocytopenic Purpura Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amgen Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Baxalta Incorporated
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Boehringer Ingelheim GmbH
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bristol-Myers Squibb Company
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Eisai
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Hansa Medical AB
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Immunomedics, Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Intas Pharmaceuticals Ltd.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Jiangsu Hengrui Medicine Co., Ltd.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Merck & Co., Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Momenta Pharmaceuticals, Inc.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Novartis AG
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Pfizer Inc.
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
